Functional Assessment of TSC2 Variants Identified in Individuals with Tuberous Sclerosis Complex

被引:58
作者
Hoogeveen-Westerveld, Marianne [1 ]
Ekong, Rosemary [2 ]
Povey, Sue [2 ]
Mayer, Karin [3 ]
Lannoy, Nathalie [4 ]
Elmslie, Frances [5 ]
Bebin, Martina [6 ]
Dies, Kira [7 ]
Thompson, Catherine [8 ]
Sparagana, Steven P. [8 ,9 ]
Davies, Peter [10 ]
van den Ouweland, Ans [1 ]
Halley, Dicky [1 ]
Nellist, Mark [1 ]
机构
[1] Erasmus MC, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands
[2] UCL, Res Dept Genet Evolut & Environm, London, England
[3] Ctr Human Genet & Lab Med, Martinsried, Germany
[4] Ctr Human Genet, Brussels, Belgium
[5] St George Hosp, Dept Med Genet, London, England
[6] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA
[7] Childrens Hosp, Dept Neurol, Boston, MA 02115 USA
[8] Texas Scottish Rite Hosp Children, Dept Neurol, Dallas, TX 75219 USA
[9] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[10] Cardiff Univ, Inst Med Genet, Cardiff CF10 3AX, S Glam, Wales
关键词
tuberous sclerosis complex; TSC2; unclassified variants; functional assay; HAMARTIN COMPLEX; CELL-GROWTH; MUTATIONS; GENE; PHOSPHORYLATION; AKT;
D O I
10.1002/humu.22202
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in the TSC1 or TSC2 genes. The TSC1 and TSC2 gene products, TSC1 and TSC2, form a complex that inhibits the mammalian target of rapamycin (mTOR) complex 1 (TORC1). Here, we investigate the effects of 78 TSC2 variants identified in individuals suspected of TSC, on the function of the TSC1-TSC2 complex. According to our functional assessment, 40 variants disrupted the TSC1-TSC2-dependent inhibition of TORC1. We classified 34 of these as pathogenic, three as probably pathogenic and three as possibly pathogenic. In one case, a likely effect on splicing as well as an effect on function was noted. In 15 cases, our functional assessment did not agree with the predictions of the SIFT amino acid substitution analysis software. Our data support the notion that different, non-terminating TSC2 mutations can have distinct effects on TSC1-TSC2 function, and therefore, on TSC pathology. Hum Mutat 34:167-175, 2013. (C) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:167 / 175
页数:9
相关论文
共 23 条
[1]   The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination [J].
Benvenuto, G ;
Li, SW ;
Brown, SJ ;
Braverman, R ;
Vass, WC ;
Cheadle, JP ;
Halley, DJJ ;
Sampson, JR ;
Wienecke, R ;
DeClue, JE .
ONCOGENE, 2000, 19 (54) :6306-6316
[2]   Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning [J].
Cai, SL ;
Tee, AR ;
Short, JD ;
Bergeron, JM ;
Kim, J ;
Shen, JJ ;
Guo, RF ;
Johnson, CL ;
Kiguchi, K ;
Walker, CL .
JOURNAL OF CELL BIOLOGY, 2006, 173 (02) :279-289
[3]   TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase [J].
Chong-Kopera, H ;
Inoki, K ;
Li, Y ;
Zhu, TQ ;
Garcia-Gonzalo, FR ;
Rosa, JL ;
Guan, KL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (13) :8313-8316
[4]   A reliable cell-based assay for testing unclassified TSC2 gene variants [J].
Coevoets, Ricardo ;
Arican, Sermin ;
Hoogeveen-Westerveld, Marianne ;
Simons, Erik ;
van den Ouweland, Ans ;
Halley, Dicky ;
Nellist, Mark .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2009, 17 (03) :301-310
[5]   The GTPase-activating protein Rap1GAP uses a catalytic asparagine [J].
Daumke, O ;
Weyand, M ;
Chakrabarti, PP ;
Vetter, IR ;
Wittinghofer, A .
NATURE, 2004, 429 (6988) :197-201
[6]   Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence [J].
Dunlop, Elaine A. ;
Dodd, Kayleigh M. ;
Land, Stephen C. ;
Davies, Peter A. ;
Martins, Nicole ;
Stuart, Helen ;
McKee, Shane ;
Kingswood, Chris ;
Saggar, Anand ;
Corderio, Isabel ;
Medeira, Ana Maria Duarte ;
Kingston, Helen ;
Sampson, Julian R. ;
Davies, David Mark ;
Tee, Andrew R. .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2011, 19 (07) :789-795
[7]   Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin [J].
Hodges, AK ;
Li, SW ;
Maynard, J ;
Parry, L ;
Braverman, R ;
Cheadle, JP ;
DeClue, JE ;
Sampson, JR .
HUMAN MOLECULAR GENETICS, 2001, 10 (25) :2899-2905
[8]   Functional Assessment of Variants in the TSC1 and TSC2 Genes Identified in Individuals with Tuberous Sclerosis Complex [J].
Hoogeveen-Westerveld, Marianne ;
Wentink, Marjolein ;
van den Heuvel, Diana ;
Mozaffari, Melika ;
Ekong, Rosemary ;
Povey, Sue ;
den Dunnen, Johan T. ;
Metcalfe, Kay ;
Vallee, Stephanie ;
Krueger, Stefan ;
Bergoffen, JoAnn ;
Shashi, Vandana ;
Elmslie, Frances ;
Kwiatkowski, David ;
Sampson, Julian ;
Vidales, Concha ;
Dzarir, Jacinta ;
Garcia-Planells, Javier ;
Dies, Kira ;
Maat-Kievit, Anneke ;
van den Ouweland, Ans ;
Halley, Dicky ;
Nellist, Mark .
HUMAN MUTATION, 2011, 32 (04) :424-435
[9]   The TSC1-TSC2 complex: a molecular switchboard controlling cell growth [J].
Huang, Jingxiang ;
Manning, Brendan D. .
BIOCHEMICAL JOURNAL, 2008, 412 :179-190
[10]   TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling [J].
Inoki, K ;
Li, Y ;
Zhu, TQ ;
Wu, J ;
Guan, KL .
NATURE CELL BIOLOGY, 2002, 4 (09) :648-657